Filing Details
- Accession Number:
- 0001209191-17-051077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-01 18:55:16
- Reporting Period:
- 2017-09-01
- Accepted Time:
- 2017-09-01 17:55:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628738 | Audentes Therapeutics Inc. | BOLD | Biological Products, (No Disgnostic Substances) (2836) | 461606174 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1679129 | Suyash Prasad | C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108 | Senior Vp & Chief Med Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-09-01 | 8,000 | $0.79 | 8,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-09-01 | 8,000 | $21.44 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2017-09-01 | 8,000 | $0.00 | 8,000 | $0.79 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 88,870 | 2024-02-18 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
Billionaire Hedge Funds
